Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer's Trials

Core Insights - Oral semaglutide, the active ingredient in the obesity and diabetes medications Ozempic and Wegovy, did not demonstrate efficacy in slowing the progression of Alzheimer's disease in two late-stage clinical trials [1] Group 1 - The clinical trials aimed to evaluate the potential of oral semaglutide in treating Alzheimer's disease [1] - Results from the trials indicate that oral semaglutide does not provide the expected benefits for Alzheimer's patients [1] - The findings may impact the perception and market potential of Ozempic and Wegovy beyond their current applications in obesity and diabetes management [1]